Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Epstein-Barr Virus Infection Promotes Epithelial Cell Growth by Attenuating Differentiation-Dependent Exit from the Cell Cycle.

Eichelberg MR, Welch R, Guidry JT, Ali A, Ohashi M, Makielski KR, McChesney K, Van Sciver N, Lambert PF, Keleș S, Kenney SC, Scott RS, Johannsen E.

MBio. 2019 Aug 20;10(4). pii: e01332-19. doi: 10.1128/mBio.01332-19.

2.

Development of a novel inducer for EBV lytic therapy.

Tikhmyanova N, Paparoidamis N, Romero-Masters J, Feng X, Mohammed FS, Reddy PAN, Kenney SC, Lieberman PM, Salvino JM.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2259-2264. doi: 10.1016/j.bmcl.2019.06.034. Epub 2019 Jun 22.

PMID:
31255485
3.

An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.

Romero-Masters JC, Ohashi M, Djavadian R, Eichelberg MR, Hayes M, Bristol JA, Ma S, Ranheim EA, Gumperz J, Johannsen EC, Kenney SC.

PLoS Pathog. 2018 Aug 20;14(8):e1007221. doi: 10.1371/journal.ppat.1007221. eCollection 2018 Aug.

4.

A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.

Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, Romero-Masters JC, Barlow EA, Farrell PJ, Rochford R, Kalejta RF, Johannsen EC, Kenney SC.

PLoS Pathog. 2018 Jul 27;14(7):e1007179. doi: 10.1371/journal.ppat.1007179. eCollection 2018 Jul.

5.

Human Cytomegalovirus Productively Replicates In Vitro in Undifferentiated Oral Epithelial Cells.

Weng C, Lee D, Gelbmann CB, Van Sciver N, Nawandar DM, Kenney SC, Kalejta RF.

J Virol. 2018 Jul 31;92(16). pii: e00903-18. doi: 10.1128/JVI.00903-18. Print 2018 Aug 15.

6.

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA.

Clin Cancer Res. 2018 Jul 15;24(14):3273-3281. doi: 10.1158/1078-0432.CCR-17-2685. Epub 2018 Apr 9.

7.

Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.

Zumwalde NA, Sharma A, Xu X, Ma S, Schneider CL, Romero-Masters JC, Hudson AW, Gendron-Fitzpatrick A, Kenney SC, Gumperz JE.

JCI Insight. 2017 Jul 6;2(13). pii: 93179. doi: 10.1172/jci.insight.93179. eCollection 2017 Jul 6.

8.

Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.

Kraus RJ, Yu X, Cordes BA, Sathiamoorthi S, Iempridee T, Nawandar DM, Ma S, Romero-Masters JC, McChesney KG, Lin Z, Makielski KR, Lee DL, Lambert PF, Johannsen EC, Kenney SC, Mertz JE.

PLoS Pathog. 2017 Jun 15;13(6):e1006404. doi: 10.1371/journal.ppat.1006404. eCollection 2017 Jun.

9.

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.

Bilger A, Plowshay J, Ma S, Nawandar D, Barlow EA, Romero-Masters JC, Bristol JA, Li Z, Tsai MH, Delecluse HJ, Kenney SC.

Oncotarget. 2017 Jul 4;8(27):44266-44280. doi: 10.18632/oncotarget.17863.

10.

Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.

Nawandar DM, Ohashi M, Djavadian R, Barlow E, Makielski K, Ali A, Lee D, Lambert PF, Johannsen E, Kenney SC.

J Virol. 2017 Mar 29;91(8). pii: e02438-16. doi: 10.1128/JVI.02438-16. Print 2017 Apr 15.

11.

Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Ma SD, Tsai MH, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol JA, Delecluse HJ, Kenney SC.

J Virol. 2017 Mar 13;91(7). pii: e01928-16. doi: 10.1128/JVI.01928-16. Print 2017 Apr 1.

12.

Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency.

Wille CK, Li Y, Rui L, Johannsen EC, Kenney SC.

J Virol. 2017 Feb 14;91(5). pii: e01987-16. doi: 10.1128/JVI.01987-16. Print 2017 Mar 1.

13.

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ.

Clin Cancer Res. 2016 Oct 1;22(19):4901-4912. Epub 2016 Jun 13.

14.

PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.

Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, Gumperz JE, Kenney SC.

PLoS Pathog. 2016 May 17;12(5):e1005642. doi: 10.1371/journal.ppat.1005642. eCollection 2016 May.

15.

Human papillomavirus promotes Epstein-Barr virus maintenance and lytic reactivation in immortalized oral keratinocytes.

Makielski KR, Lee D, Lorenz LD, Nawandar DM, Chiu YF, Kenney SC, Lambert PF.

Virology. 2016 Aug;495:52-62. doi: 10.1016/j.virol.2016.05.005. Epub 2016 May 11.

16.

5-hydroxymethylation of the EBV genome regulates the latent to lytic switch.

Wille CK, Nawandar DM, Henning AN, Ma S, Oetting KM, Lee D, Lambert P, Johannsen EC, Kenney SC.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7257-65. doi: 10.1073/pnas.1513432112. Epub 2015 Dec 9.

17.

Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells.

Nawandar DM, Wang A, Makielski K, Lee D, Ma S, Barlow E, Reusch J, Jiang R, Wille CK, Greenspan D, Greenspan JS, Mertz JE, Hutt-Fletcher L, Johannsen EC, Lambert PF, Kenney SC.

PLoS Pathog. 2015 Oct 2;11(10):e1005195. doi: 10.1371/journal.ppat.1005195. eCollection 2015 Oct.

18.

LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, Asimakopoulos F, Tang W, Gulley ML, Cesarman E, Gumperz JE, Kenney SC.

J Clin Invest. 2015 Jan;125(1):304-15. doi: 10.1172/JCI76357. Epub 2014 Dec 8.

19.

Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.

Reusch JA, Nawandar DM, Wright KL, Kenney SC, Mertz JE.

J Virol. 2015 Feb;89(3):1731-43. doi: 10.1128/JVI.02781-14. Epub 2014 Nov 19.

20.

Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Iempridee T, Reusch JA, Riching A, Johannsen EC, Dovat S, Kenney SC, Mertz JE.

J Virol. 2014 May;88(9):4811-27. doi: 10.1128/JVI.03706-13. Epub 2014 Feb 12.

21.

Regulation of the latent-lytic switch in Epstein-Barr virus.

Kenney SC, Mertz JE.

Semin Cancer Biol. 2014 Jun;26:60-8. doi: 10.1016/j.semcancer.2014.01.002. Epub 2014 Jan 20. Review.

22.

Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.

Sun X, Bristol JA, Iwahori S, Hagemeier SR, Meng Q, Barlow EA, Fingeroth JD, Tarakanova VL, Kalejta RF, Kenney SC.

J Virol. 2013 Sep;87(18):10126-38. doi: 10.1128/JVI.01671-13. Epub 2013 Jul 10.

23.

Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease.

Lockridge JL, Zhou Y, Becker YA, Ma S, Kenney SC, Hematti P, Capitini CM, Burlingham WJ, Gendron-Fitzpatrick A, Gumperz JE.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1310-22. doi: 10.1016/j.bbmt.2013.06.007. Epub 2013 Jun 24.

24.

The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.

Raver RM, Panfil AR, Hagemeier SR, Kenney SC.

J Virol. 2013 Jul;87(14):8053-63. doi: 10.1128/JVI.00546-13. Epub 2013 May 15.

25.

Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.

Wille CK, Nawandar DM, Panfil AR, Ko MM, Hagemeier SR, Kenney SC.

J Virol. 2013 Jan;87(2):935-50. doi: 10.1128/JVI.01790-12. Epub 2012 Nov 7.

26.

MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.

Bhatia N, Xiao TZ, Rosenthal KA, Siddiqui IA, Thiyagarajan S, Smart B, Meng Q, Zuleger CL, Mukhtar H, Kenney SC, Albertini MR, Jack Longley B.

J Invest Dermatol. 2013 Mar;133(3):759-767. doi: 10.1038/jid.2012.355. Epub 2012 Oct 25.

27.
28.

Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Hoebe EK, Wille C, Hopmans ES, Robinson AR, Middeldorp JM, Kenney SC, Greijer AE.

J Virol. 2012 Oct;86(20):11322-32. Epub 2012 Aug 15.

29.

An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML, Kenney SC.

J Virol. 2012 Aug;86(15):7976-87. doi: 10.1128/JVI.00770-12. Epub 2012 May 23.

30.

Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.

Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML.

Dig Dis Sci. 2012 Jul;57(7):1887-98. doi: 10.1007/s10620-012-2116-5. Epub 2012 Mar 13.

31.

The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.

Robinson AR, Kwek SS, Kenney SC.

PLoS Pathog. 2012 Feb;8(2):e1002516. doi: 10.1371/journal.ppat.1002516. Epub 2012 Feb 9.

32.

Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.

Robinson AR, Kwek SS, Hagemeier SR, Wille CK, Kenney SC.

J Virol. 2011 Sep;85(17):8940-53. doi: 10.1128/JVI.00569-11. Epub 2011 Jun 22.

33.

Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands.

Hegde S, Lockridge JL, Becker YA, Ma S, Kenney SC, Gumperz JE.

J Autoimmun. 2011 Aug;37(1):28-38. doi: 10.1016/j.jaut.2011.03.001. Epub 2011 Apr 12.

34.

Reactivation and lytic replication of EBV.

Kenney SC.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 25.

35.

The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner.

Hagemeier SR, Barlow EA, Kleman AA, Kenney SC.

J Virol. 2011 May;85(9):4318-29. doi: 10.1128/JVI.01856-10. Epub 2011 Feb 16.

36.

Epstein-Barr virus-specific methylation of human genes in gastric cancer cells.

Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ER, Coleman WB, Gulley ML.

Infect Agent Cancer. 2010 Dec 31;5:27. doi: 10.1186/1750-9378-5-27.

37.

A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.

Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC.

J Virol. 2011 Jan;85(1):165-77. doi: 10.1128/JVI.01512-10. Epub 2010 Oct 27.

38.

The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Bristol JA, Robinson AR, Barlow EA, Kenney SC.

J Virol. 2010 Dec;84(23):12362-74. doi: 10.1128/JVI.00712-10. Epub 2010 Sep 22.

39.

Hsp90 inhibitors: a potential treatment for latent EBV infection?

Sun X, Kenney SC.

Cell Cycle. 2010 May;9(9):1665-6. Epub 2010 May 19. No abstract available.

40.

Viral response to chemotherapy in endemic burkitt lymphoma.

Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F, Wokocha C, Kenney SC, Hoffman I, Sigel C, Maygarden S, Hoffman M, Shores C.

Clin Cancer Res. 2010 Apr 1;16(7):2055-64. doi: 10.1158/1078-0432.CCR-09-2424. Epub 2010 Mar 16.

41.

Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.

Hagemeier SR, Dickerson SJ, Meng Q, Yu X, Mertz JE, Kenney SC.

J Virol. 2010 May;84(9):4383-94. doi: 10.1128/JVI.02369-09. Epub 2010 Feb 24.

42.

The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC.

J Virol. 2010 May;84(9):4534-42. doi: 10.1128/JVI.02487-09. Epub 2010 Feb 24.

43.

Simian virus 40 T/t antigens and lamin A/C small interfering RNA rescue the phenotype of an Epstein-Barr virus protein kinase (BGLF4) mutant.

Meng Q, Hagemeier SR, Kuny CV, Kalejta RF, Kenney SC.

J Virol. 2010 May;84(9):4524-33. doi: 10.1128/JVI.02456-09. Epub 2010 Feb 10.

44.

Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.

Sun X, Barlow EA, Ma S, Hagemeier SR, Duellman SJ, Burgess RR, Tellam J, Khanna R, Kenney SC.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3146-51. doi: 10.1073/pnas.0910717107. Epub 2010 Jan 26.

45.

CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter.

Bristol JA, Morrison TE, Kenney SC.

Mol Immunol. 2009 Aug;46(13):2706-13. doi: 10.1016/j.molimm.2009.05.024. Epub 2009 Jun 11.

46.

Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo.

Ryan JL, Jones RJ, Elmore SH, Kenney SC, Miller G, Schroeder JC, Gulley ML.

Intervirology. 2009;52(1):8-16. doi: 10.1159/000210833. Epub 2009 Apr 7.

47.

Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters.

Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC.

PLoS Pathog. 2009 Mar;5(3):e1000356. doi: 10.1371/journal.ppat.1000356. Epub 2009 Mar 27.

48.

ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells.

Feng WH, Kraus RJ, Dickerson SJ, Lim HJ, Jones RJ, Yu X, Mertz JE, Kenney SC.

J Virol. 2007 Sep;81(18):10113-22. Epub 2007 Jul 11.

49.

B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus.

Yu F, Feng J, Harada JN, Chanda SK, Kenney SC, Sun R.

FEBS Lett. 2007 Jul 24;581(18):3485-8. Epub 2007 Jun 29.

50.

Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.

Jones RJ, Seaman WT, Feng WH, Barlow E, Dickerson S, Delecluse HJ, Kenney SC.

Int J Cancer. 2007 Sep 15;121(6):1274-81.

Supplemental Content

Loading ...
Support Center